Biotechnology News and Research

RSS

Women still underestimate the seriousness of heart disease

Although heart disease remains the No. 1 killer nationally for women-—responsible for one out of every three deaths—-many of today's women still underestimate the seriousness of the disease and their risks, says Liliana Cohen, MD, a board-certified cardiologist with The Robert Wood Johnson Medical Group.

4 Feb 2013

Two new methods could accelerate development of improved antisense drugs

Powerful antisense drugs that target disease-associated genes to block their expression can be used to treat a broad range of diseases. Though antisense therapy has been proven effective, challenges remain in ensuring that the drugs reach their intended targets.

2 Feb 2013

Book reviews psilocybin's potential in alleviating psychological distress in cancer patients

Improvements in the diagnosis and treatment of cancers in recent years have led to a marked increase in patients' physical survival rates. While doctors can treat the physical disease, what is not well understood is how best to address the psychological needs of patients with cancer.

1 Feb 2013

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications.

1 Feb 2013

Obesity becoming serious problem, comparable to cigarette smoking

Dr. Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published a report in the current issue of the American Journal of Medicine that obesity is becoming as big a hazard worldwide, comparable to cigarette smoking.

1 Feb 2013

Three Robert Wood Johnson members win Edward J. Ill Excellence in Medicine Awards

Three members of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School faculty have been named 2013 recipients of the prestigious Edward J. Ill Excellence in Medicine Awards, highlighting their expertise as exceptional educators or researchers.

1 Feb 2013

Mental health in young people: an interview with Professor Colum Dunne

Ireland, and many other countries, is witnessing increases in problematic and complex youth mental health challenges. In Ireland, specifically, there has been a rash of high profile cases where young people have unfortunately not been able to deal with stress, bullying and other issues.

1 Feb 2013

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197).

31 Jan 2013

SINEUP allows scientists to target individual genes in cells to increase protein production

One of the most innovative biotechnologies of the last decade has recently been developed. SINEUP allows scientists, for the first time, to target individual genes in cells to knockup, or increase, the amount of protein they make. The technique will improve Protein manufacture, analyse the function of genes and engineer improved cell function.

From Cell Guidance Systems 31 Jan 2013

Optofluidics to pre-launch Molecular NanoTweezer system in Feb. 2013

Optofluidics announces the pre-release of its Molecular NanoTweezer system - the most powerful optical trapping technology in the world - at SPIE Photonics West, BiOS and Biophysical Society annual meetings in Feb. 2013.

From Halo Labs 31 Jan 2013

Affymetrix fourth quarter total revenue increases 2% to $84.4 million

Affymetrix, Inc., today reported its operating results for the three and twelve months ended December 31, 2012.

31 Jan 2013

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.

31 Jan 2013

Teva terminates collaboration with CureTech

Teva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.

31 Jan 2013

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient.

31 Jan 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

Increasing age, male sex and adiposity risk factors for metabolic syndrome in children

Metabolic syndrome is more likely to affect children who are obese than overweight or non-overweight and who have other characteristics associated with the disorder, such as high blood pressure or insulin resistance. A new comprehensive and systematic review of the medical literature on metabolic syndrome in children that probed deeper to evaluate the risk associated with gender, ethnicity, and geography was published in Metabolic Syndrome and Related Disorders, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

31 Jan 2013

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).

31 Jan 2013

Existing cardiomyocytes contribute to formation of new heart cells after attack

Injecting specialized cardiac stem cells into a patient's heart rebuilds healthy tissue after a heart attack, but where do the new cells come from and how are they transformed into functional muscle?

31 Jan 2013

Supplementation with omega-3 fatty acids promotes effective immune system response

Supplementation with omega-3 fatty acids promotes effective immune system response and has ameliorating effects on chronic inflammation (a condition caused by an imbalanced immune system that can lead to multiple serious illnesses over time), according to the most recent study published by the National Center for Biotechnology Information on the effects of omega-3.

31 Jan 2013

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.

From QIAGEN Manchester Limited 30 Jan 2013

Biotechnology News and Research

Women still underestimate the seriousness of heart disease

Two new methods could accelerate development of improved antisense drugs

Book reviews psilocybin's potential in alleviating psychological distress in cancer patients

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Obesity becoming serious problem, comparable to cigarette smoking

Three Robert Wood Johnson members win Edward J. Ill Excellence in Medicine Awards

Mental health in young people: an interview with Professor Colum Dunne

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

SINEUP allows scientists to target individual genes in cells to increase protein production

Optofluidics to pre-launch Molecular NanoTweezer system in Feb. 2013

Affymetrix fourth quarter total revenue increases 2% to $84.4 million

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Teva terminates collaboration with CureTech

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Increasing age, male sex and adiposity risk factors for metabolic syndrome in children

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Existing cardiomyocytes contribute to formation of new heart cells after attack

Supplementation with omega-3 fatty acids promotes effective immune system response

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News